Axol Bioscience Ltd., a Cambridge, England, UK-based supplier of iPSC-derived cells, media, and characterization companies for all times science discovery, raised £3.2m GBP (circa $4.2m USD).
The spherical, the extension of its earlier funding spherical, bringing the whole raised to £7m GBP (circa $9.2m USD) – was led by present traders Calculus Capital, Par Fairness and Scottish Enterprise, with help from Meltwind, together with early investor Dr Jonathan Milner.
The funds shall be used to carry new human induced pluripotent stem cell (iPSC) merchandise and repair options for cardiac, neuroscience, and immune cell modeling to the drug discovery and screening markets, together with Axol’s just lately developed complete in vitro proarrhythmia assay (CiPA)-validated human iPSC-derived cardiomyocytes. Funding will allow the corporate to additional optimize cell tradition high quality and iPSC manufacturing capabilities at its Edinburgh, UK, web site based mostly on the Roslin Institute, in addition to help recruitment efforts to broaden its industrial workforce. It’s going to additionally facilitate the continued improvement of its digital platform.
Axol is led by Liam Taylor, CEO, and Dr Thomas Stratford, Interim Chairman.